

Pennsylvania's Opioid Settlements

The United States is in the **midst of a crisis** on its streets and in its communities as **overdoses, homelessness, and disorder reach record levels**. Yet settlement proceeds secured by the Commonwealth of Pennsylvania present an **unprecedented opportunity for generational investment** in treatment capacity for chronic substance abuse (CSA) and severe mental illness (SMI).

Pennsylvania is set to receive **more than \$2 billion** (\$2,036,354,999.62) in opioid settlement funds—equal to nearly one-fourth of the commonwealth's share of the monumental Tobacco Master Settlement Agreement.¹ With twenty separate settlements and payments spread out over decades, the funds are **at risk of being squandered** through ad-hoc allocations to **diffuse and disorganized efforts**.

The commonwealth must ensure that this opportunity for treatment investment is not underutilized. **Pennsylvania can make targeted investments in treatment capacity** that will **honor those who suffered** in the opioid crisis and **ensure accessible care** for decades to come.

Pennsylvania reserves only 15 percent of funds (\$340,722,329.22) for use by the commonwealth with the remainder allocated to counties and subdivisions.¹ The commonwealth's share is held in the Opioid Settlement Restricted Account and allocable by the legislature.^{2,3} Unfortunately, these percentages are established pursuant to a court order and are not easily amended. **If possible, the commonwealth should enact an allocation statute securing a greater portion of opioid funds for allocation by the legislature.** Reporting on current uses of funds is not available, and thus sufficient oversight is not possible. **The commonwealth should report annually on uses of funds to allow sufficient oversight.**

The commonwealth must rein in the potential misallocation of these funds and prioritize investments in comprehensive treatment networks. **Three priorities** (Certified Community Behavioral Health Clinics, secure psychiatric beds, and community SMI/CSA response) **will ensure these funds have the largest impact** on Pennsylvania.

¹ With the exception of the McKinsey and Publicis settlements, in which 100 percent of funds are deposited into the restricted account.

Certified Community Behavioral Health Clinics (CCBHCs)

CCBHCs, designed to ensure access to coordinated comprehensive behavioral health care, have stable funding and are supported by all recent presidential administrations. CCBHCs are a key response to the opioid crisis and can augment other services such as police crisis response teams, homelessness outreach and services, and outpatient psychiatric commitment services.

- **Solution: Fund the development and expansion of CCBHCs.**
 - o Expand the CCBHC footprint with an emphasis on a team-based approach to co-occurring disorders.
 - o Create a stepped approach to SMI/CSA treatment with services provided by the CCBHCs.
 - o Require CCBHCs to offer specific care pathways to meet the needs of individuals with co-occurring disorders.

State Psychiatric Hospitals

Inpatient beds in secure facilities are critical for serving the highest-acuity psychiatric patients. Pennsylvania currently has only **7.9 state psychiatric beds** per 100,000 people available for civil (i.e., non-criminal) patients.⁴⁵ Treatment Advocacy Center recommends a rate of 30-60 beds per 100,000. Even counting non-public secure psychiatric beds, Pennsylvania still falls short of the minimum.⁶ Secure beds are a costly but necessary expenditure to protect patients with severe psychiatric disorders and the public at large.

- **Solution: Fund the expansion of civil psychiatric beds.**
 - o Invest in expanding state hospital capacity.
 - o Move forensic (criminal) commitments to a jail-based restoration facility.
 - o Apply for one of several Section 1115(a) waivers to expand Medicaid reimbursement for institutions for mental diseases (IMDs).

Inpatient Stabilization Centers and Mobile Crisis Teams

Emergency departments (EDs) are supposed to be a last resort for times of true emergencies, but are increasingly used for all types of immediate-need medical care. This is especially true for low- to medium-acuity mental health crises. In order for CCBHCs and state psychiatric bed expansions to have the largest impact, there must be an immediate triage of low-acuity patients from higher-need patients, or else investments in these facilities will be drowned out, overburdened, and underutilized by those that need them most, just like emergency departments.

- **Solution: Fund community-based mental health response resources.**
 - Expand community-based recovery centers, including voluntary short-term respite housing, especially for young adults.
 - Leverage CCBHC resources to develop comprehensive mobile crisis response teams in conjunction with police crisis intervention teams (CIT).
 - Support integration of community resources with crisis networks such as the Lifeline to support those in need or provide guidance for concerned loved ones.

PENNSYLVANIA

[Download all Pennsylvania opioid settlement documents](#)

[View settlement fund dashboard](#)

STATE-CONTROLLED FUNDS	ALL FUNDS	2025 EOY FUNDS RECEIVED - STATE	2025 EOY FUNDS RECEIVED - ALL	Av. Receipt (All Funds) / Yr (*20)
\$340,722,329.22	\$2,036,354,999.62	\$142,037,511.90	\$711,789,550.93	\$101,817,749.98

2021 National Opioid Settlement

Pennsylvania v. Distributors

- [Entry of Final Consent Judgment](#)
- [Final Consent Judgment](#)
 - AmerisourceBergen Corporation Secretary's Certificate [p. 15]
 - Corporate Secretary's Certificate of McKesson Corporation [p. 16]
 - Cardinal Health Secretary's Certificate [p. 20]
 - Exhibit A "Distributor Settlement Agreement" [p. 21]
 - Exhibit B "Pennsylvania Opioid Misuse and Addiction Abatement Trust" [p. 593]
- Commonwealth of Pennsylvania by Attorney General Josh Shapiro v. Amerisourcebergen Corporation, et al., Commonwealth Court of Pennsylvania, Case No. 244 M.D. 2022

Pennsylvania v. Janssen

- [Final Consent Judgment](#)
- Order granting the Joint Motion to Enter Final Consent Judgment [p. 1]
- Joint Motion to Enter Final Consent Judgment [p. 3]
- Final Consent Judgment with Johnson & Johnson Respondents [p. 8]
- Exhibit A "Janssen Settlement" [p. 24]
- Exhibit B "Pennsylvania Opioid Misuse and Addiction Abatement Trust [p. 534]
- Commonwealth of Pennsylvania by Attorney General Josh Shapiro v. Johnson & Johnson, et al., Commonwealth Court of Pennsylvania, Case No. 243 M.D. 2022

2022 National Opioid Settlement

Pennsylvania v. CVS

- [Entry of Final Consent Judgment](#)
- [Final Consent Judgment](#)
 - [Exhibit A "agreement dated as of December 9, 2022"](#)
 - [Exhibit B "Pennsylvania Opioid Misuse and Addiction Abatement Trust Order"](#)
- Commonwealth of Pennsylvania, Acting by Attorney General Michelle Henry, vs. CVS Pharmacy, Inc. et al., Commonwealth Court of Pennsylvania, Case No. 58 MD 2024

Pennsylvania v. Walgreens

- [Entry of Final Consent Judgment](#)
- [Final Consent Judgment](#)
 - [Exhibit A “agreement dated as of December 9, 2022”](#)
 - [Exhibit B “Pennsylvania Opioid Misuse and Addiction Abatement Trust Order”](#)
- Commonwealth of Pennsylvania, Acting by Attorney General Michelle Henry, vs. CVS Pharmacy, Inc. et al., Commonwealth Court of Pennsylvania, Case No. 58 MD 2024

Pennsylvania v. Walmart

- [Entry of Final Consent Judgment](#)
- [Final Consent Judgment](#)
 - [Exhibit A “agreement dated as of November 14, 2022”](#)
 - [Exhibit B “Pennsylvania Opioid Misuse and Addiction Abatement Trust Order”](#)
- Commonwealth of Pennsylvania, Acting by Attorney General Michelle Henry, vs. CVS Pharmacy, Inc. et al., Commonwealth Court of Pennsylvania, Case No. 58 MD 2024

Pennsylvania v. Allergan

- [Entry of Final Consent Judgment](#)
- [Final Consent Judgment](#)
 - [Exhibit A “Allergan Public Global Opioid Settlement Agreement”](#)
 - [Exhibit B “Pennsylvania Opioid Misuse and Addiction Abatement Trust Order”](#)
- Commonwealth of Pennsylvania, Acting by Attorney General Michelle Henry, v. Allergan Limited, et al., Commonwealth Court of Pennsylvania, Case No. 59 M.D. 2024

Pennsylvania v. Teva

- [Entry of Final Consent Judgment](#)
- [Final Consent Judgment](#)
 - [Exhibit A “Teva Global Opioid Settlement Agreement”](#)
 - [Exhibit B “Pennsylvania Opioid Misuse and Addiction Abatement Trust Order”](#)
- Commonwealth of Pennsylvania, Acting by Attorney General Michelle Henry, v. Allergan Limited, et al., Commonwealth Court of Pennsylvania, Case No. 59 M.D. 2024

Other Coalition Opioid Settlements

Pennsylvania v. McKinsey

- [Final Consent Judgment](#)
- [McKinsey Allocation Amounts](#)
- Commonwealth of Pennsylvania by Attorney General Josh Shapiro v. McKinsey & Company, Inc., United States, Commonwealth Court of Pennsylvania, Case No. 24 M.D. 2021

Pennsylvania v. Mallinckrodt

- [NOAT II Agreement](#)
- [Statewide Abatement Agreement](#)
- [Notice of Abatement Distribution](#)

Pennsylvania v. Publicis

- [Final Consent Judgment](#)
- Commonwealth of Pennsylvania, Acting by Attorney General, Michelle Henry, v. Publicis Health, LLC, Commonwealth Court of Pennsylvania, Case No. 43 M.D. 2024

Pennsylvania v. Endo

- [Global Public Trust Agreement](#)
- [Notice of Abatement Distribution](#)

2025 National Settlements

Pennsylvania v. Purdue

- [missing documentation]
- Commonwealth of Pennsylvania by Attorney General Josh Shapiro v. Purdue Pharma L.P., et al., Commonwealth Court of Pennsylvania, Case No. 257-md-19 [unconfirmed]

Pennsylvania v. Mylan

- [missing documentation]

Pennsylvania v. Hikma

- [missing documentation]

Pennsylvania v. Amneal

- [missing documentation]

Pennsylvania v. Apotex

- [missing documentation]

Pennsylvania v. Indivior

- [missing documentation]

Pennsylvania v. Sun Pharmaceuticals

- [missing documentation]

Pennsylvania v. Alvogen

- [missing documentation]

Pennsylvania v. Zydus

- [missing documentation]

Independent Settlements

¹ KFF. "Actual Tobacco Settlement Payments Received by the States (in millions)." Accessed 8 September 2025.

<https://www.kff.org/health-costs/state-indicator/tobacco-settlement-payments>.

² Third Annual Report of the Pennsylvania Opioid Misuse and Addiction Abatement Trust, p. 12.

<https://paopioidtrust.org/getattachment/43268764-79ea-45e3-b835-5d392c53a0e3/9-10-2025-FILED-Third-Annual-Report-of-PAOMAAT.pdf>.

³ 72 P.S. § 1792-A.1.

<https://govt.westlaw.com/pac/Document/N700D8E100F4511ED9F16A28B36828493?originationContext=document&transitionType=StatuteNavigator&needToInjectTerms=False&viewType=FullText&ppcid=a60e86aac39481bbbe49991aea94055&contextData=%28sc.Default%29>.

⁴ Treatment Advocacy Center, "Pennsylvania Psychiatric Beds Report." 2023. <https://www.tac.org/wp-content/uploads/2023/10/Pennsylvaniabedsinformation.pdf>.

⁵ United States Census Bureau, "2023 American Community Survey – Total Population."

[https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US\\$0400000](https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US$0400000).

⁶ Silver, Shanti, "Estimating Psychiatric Bed Need in the United States," p. 2-4. Treatment Advocacy Center Office of Research and Public Affairs. January 2024. https://www.tac.org/wp-content/uploads/2024/03/TAC_ORPA_ResearchSummary1.24.pdf.